Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Kristin M. Savill, Adeola Y. Makinde

Blood (2022) 140 (Supplement 1): 944–946.

https://doi.org/10.1182/blood-2022-156902

Published: 2022

Journal Articles

Real-World (RW) Evaluation of Acute Myeloid Leukemia (AML) Induction Therapies in the Community Setting: A Retrospective Evaluation of Outcomes of Intensive Chemotherapy, Venetoclax-Based Regimens, and Non-IC-Based Treatments

Keri Maher, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Djibril Liassou, Ying Qiu, Marné Garretson, JaLyna Laney, David Huggar, David Hughes

Blood (2022) 140 (Supplement 1): 13278–13279.

https://doi.org/10.1182/blood-2022-169762

Published: 2022

Journal Articles

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Sudipto Mukherjee, Kristin M. Savill, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Ali McBride

Blood (2022) 140 (Supplement 1): 10998–11000.

https://doi.org/10.1182/blood-2022-156892

Published: 2022

Journal Articles

Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices

Ajeet Gajra, Jonathan K. Kish, Alexander Russell-Smith, Kristin M. Savill

Blood (2022) 140 (Supplement 1): 5296–5297.

https://doi.org/10.1182/blood-2022-163621

Published: 2022

Journal Articles

Real-World Treatment of Patients with Large B-Cell Lymphoma in the United States with Chimeric Antigen Receptor T-Cell Therapy

Kristin M. Zimmerman Savill, Andrew J Klink, Djibril Liassou, Dhruv Chopra, Jalyna Laney, Ajeet Gajra

Blood (2021) 138 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2021-150723

Published: 2021

Journal Articles

Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O)

Ajeet Gajra, Yolaine Jeune-Smith, Bruce A. Feinberg

Blood (2021) 138 (Supplement 1): 4010.

https://doi.org/10.1182/blood-2021-151789

Published: 2021

Journal Articles

U.S-Based Community Oncologists/Hematologists' Perceptions Regarding Future Use of Gene Therapies for Patients with Hematological Disorders

Ajeet Gajra, Stephanie Fortier, Yolaine Jeune-Smith, Bruce A. Feinberg

Blood (2021) 138 (Supplement 1): 2986.

https://doi.org/10.1182/blood-2021-148165

Published: 2021

Journal Articles

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Kristin M. Zimmerman Savill, Ajeet Gajra, Kwanza Price, Jonathan K. Kish, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Talia Miller, JaLyna Laney, Sudipto Mukherjee

Blood (2021) 138 (Supplement 1): 4657.

https://doi.org/10.1182/blood-2021-146461

Published: 2021

Journal Articles

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Eli G Phillips, Jr., PharmD, JD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142064

Published: 2020

Journal Articles

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Marjorie E Zettler, PhD MPH, Bruce Feinberg, DO, Alexandrina Balanean, Ajeet Gajra, MD MBBS

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142061

Published: 2020

Journal Articles

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Ajeet Gajra, MD MBBS, Yamini S Rathish, Yolaine Jeune-Smith, PhD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142005

Published: 2020

Journal Articles

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Ajeet Gajra, MD MBBS, Skyler Hime, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141990

Published: 2020

Journal Articles

Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death

Andrew J Klink, PhD MPH, Ronda Copher, PhD, Russell L. Knoth, Landon Marshall, PharmD, PhD, Ying Hou, MD, Ajeet Gajra, MD MBBS, Raoul Tibes, MD PhD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-140005

Published: 2020

Journal Articles

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-142069

Published: 2020

Journal Articles

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, PhD MPH, Bruce A Feinberg, DO, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Sonam Mehta, Ajeet Gajra, MD FACP

Blood (2019) 134 (Supplement_1): 1951.

https://doi.org/10.1182/blood-2019-127372

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Jonathan K. Kish, PhD MPH, Bruce A Feinberg, DO

Blood (2019) 134 (Supplement_1): 2198.

https://doi.org/10.1182/blood-2019-127741

Published: 2019

Journal Articles

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Marjorie E Zettler, PhD MPH, Chadi Nabhan, MDMBA, FACP, Ajeet Gajra, MD FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 3490.

https://doi.org/10.1182/blood-2019-129553

Published: 2019

Journal Articles

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5822.

https://doi.org/10.1182/blood-2019-129502

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

NARROW

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Real-World (RW) Evaluation of Acute Myeloid Leukemia (AML) Induction Therapies in the Community Setting: A Retrospective Evaluation of Outcomes of Intensive Chemotherapy, Venetoclax-Based Regimens, and Non-IC-Based Treatments

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices

Real-World Treatment of Patients with Large B-Cell Lymphoma in the United States with Chimeric Antigen Receptor T-Cell Therapy

Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O)

U.S-Based Community Oncologists/Hematologists' Perceptions Regarding Future Use of Gene Therapies for Patients with Hematological Disorders

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only